NovoCure Ltd. (NVCR)
NASDAQ:NVCR
Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$12.83
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.83
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$9.82 - $20.06
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.69M
Market Cap
$2.02B
Enterprise Value$2.11B
Total Cash (Recent Filing)$441.80M
Total Debt (Recent Filing)$234.94M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Jul 23, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding115,820,940
10 Day Avg. Volume1,733,669
30 Day Avg. Volume1,689,667
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue3.13
Enterprise Value/Gross Profit4.16
Enterprise Value/Ebitda-13.18
Forecast
1Y Price Target
$26.17Price Target Upside103.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.59
Revenue Forecast (FY)$703.91M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPANOVA-4 Phase 2 meeting its disease control rate primary endpoint indicates the Optune Pax combination demonstrated clinical activity in metastatic pancreatic cancer, supporting further clinical development.
Commercial Strategy And Financial OutlookLeveraging existing commercial and field teams for the pancreatic launch reduces the need for additional sales hires and limits upfront capital requirements, aiding the path toward adjusted EBITDA break-even.
Regulatory ApprovalFDA approval for Optune Pax in locally advanced pancreatic cancer, supported by randomized trial data showing a survival benefit, strengthens the therapy's credibility with clinicians and payers.
Bears Say
Clinical Efficacy UncertaintyObjective response rate and median overall survival not showing a clear advantage versus historical control raises uncertainty about the regimen's likelihood of succeeding in a confirmatory Phase 3 study.
Competitive Landscape And Commercial FocusA crowded metastatic pancreatic cancer development environment with newer targeted therapies, combined with scaled-back commercial efforts for the non-small cell lung cancer indication, may pressure market share and near-term sales growth.
Reimbursement And Billing RiskRevocation of Medicare billing privileges and the current inability to bill Medicare or Medicare Advantage could delay material revenue recognition until billing privileges are reinstated and reimbursement codes are secured.
NovoCure News
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $9.82 and its highest was $20.06 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $2.02B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Jul 23, 2026 which is in 64 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Apr 30, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.108.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.33.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 115,820,940 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went up 27.494%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.17 (103.95% Upside)
$26.17 (103.95% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 55.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $595.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.40%
12-Months-Change
Fundamentals
Return on Equity
-50.82%
Trailing 12-Months
Asset Growth
-36.91%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NVCR Company Deck
NVCR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive commercial and clinical outlook anchored by a strong start to 2026: double-digit revenue growth (12% YoY), rapid Optune Pax FDA approval and early U.S. launch traction, encouraging PANOVA-4 data, gross margin improvement, and tightened adjusted EBITDA versus prior year. These positives are tempered by a sizable one-time GAAP share‑based compensation charge that materially widened GAAP net loss and drove a large G&A increase, modest near-term revenue contribution from new indications, remaining reimbursement timing uncertainty, and ongoing trial strategy work for LUNAR-2. On balance, the company demonstrated substantive commercial momentum and multiple upcoming catalysts that outweigh the near-term accounting-driven losses and operational uncertainties.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$26.17
▲(103.95% Upside)
Technical Analysis
Ownership Overview
2.70% Insiders
21.41% Mutual Funds
17.84% Other Institutional Investors
42.34% Public Companies and
Individual Investors